| HOME >> BIOLOGY >> TECHNOLOGY |
PALO ALTO, Calif., Aug. 28 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases as well as dermaceutical products announced today that it has signed an exclusive worldwide distribution agreement with RITA Corporation, a leading supplier of specialty chemicals to the personal care industry. The agreement covers global rights to certain Avicena compounds for use in the personal care industry. Avicena's proprietary dermaceutical compounds incorporate the company's patented cell-nourishing technology which promotes optimal cellular regeneration and cellular protection, as well as anti-aging skin benefits.
"RITA is highly regarded as a leading, global supplier of specialty chemicals to the cosmetic and personal care industries", said Belinda Tsao-Nivaggioli, Ph.D., CEO of Avicena. "This makes RITA an ideal partner to distribute our proprietary dermaceutical ingredients and to significantly expand our existing dermaceutical business."
"We are excited to have the opportunity to distribute Avicena's scientifically based skin care ingredients", said Brian Goode, President of RITA. "The industry continues to shift toward ingredients that are backed by proven science and achieve measurable skin benefits. Avicena's products fit well into this growing trend."
ABOUT AVICENA'S DERMACEUTICAL BUSINESS
Avicena is leveraging its proprietary cellular energy technology to commercialize therapeutic dermaceutical products, as well as proprietary ingredients and formulations. Avicena's scientifically based skin care ingredients and formulations are designed to enhance the regeneration of healthier skin and to protect against the effects of aging, as well as oxidative and photo damage.
Avicena has developed Nurigene(TM), an advanced skin care regimen based
on the company's patented cell-nourishing technology which enhan
'/>"/>
| SOURCE Avicena Group, Inc. Copyright©2007 PR Newswire. All rights reserved |